Genentech eyes lupus market for Gazyva with positive Phase III data readout

[cafead]

via Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company targets the billion-dollar lupus market for its CD20-targeting drug Gazyva (obinutuzumab).

article source